A novel plasma filtration therapy for hepatic failure: Preclinical studies
A novel plasma filtration therapy for hepatic failure: Preclinical studies
复制标题
DOI：
10.1111/j.1744-9987.2006.00355.x
复制
发表时间：
2006-04-01
影响因子：
1.9
通讯作者：
Demetriou, AA
中科院分区：
文献类型：
--
作者：
Rozga, J;Umehara, Y;Demetriou, AA
需要开发肝替代和/或辅助的人工手段，目的是支持具有临界功能性肝细胞团的患者直到他们的肝再生，或者直到供体肝可用于移植。选择性血浆滤过是血液净化治疗的一种新方法，旨在降低肝和肾衰竭的循环毒素、炎症介质和肝再生抑制剂的水平。临床前研究的结果表明，治疗实验诱导的暴发性肝衰竭猪在延长生存时间和抑制脑肿胀方面是安全有效的。此外，在本研究中，在6小时治疗期间去除的氨、芳香族氨基酸、IL 6、TNF α和C3 a的量比治疗开始时这些物质的总血浆含量高34%至175%。
There is a need to develop artificial means of liver replacement and/or assistance with the aim of either supporting patients with borderline functional liver cell mass until their liver regenerates, or until a donor liver becomes available for transplantation. Selective plasma filtration is a novel approach to blood purification therapy designed to reduce the level of circulating toxins of hepatic and renal failure, mediators of inflammation and inhibitors of hepatic regeneration. The results of preclinical studies indicate that treatment of pigs with experimentally-induced fulminant hepatic failure is safe and effective in extending survival time and arresting brain swelling. In addition, the amount of ammonia, aromatic amino acids, IL6, TNF alpha and C3a removed during the 6-h treatment in the present study was higher by 34% to 175% than the total plasma content of those substances at the start of therapy.